ORIC Pharmaceuticals reports Q2 GAAP EPS of -$0.38, missing estimates by $0.02

Earnings
โดย Seeking Alpha·Read original
Summary · why it matters

ORIC Pharmaceuticals reported a second-quarter GAAP loss of $0.38 per share, missing analyst estimates by $0.02. The company held cash, cash equivalents, and investments totaling $387.6 million as of June 30, 2026, which includes $59.9 million in net proceeds raised from healthcare specialist funds during the first quarter under its at-the-market program. ORIC expects its cash and investments to fund the operating plan into the second half of 2028.

Impact on stocks 1

Biotech & Genomic Medicine▼ · 1 stocks
© 2026 MarketDXNews